265 related articles for article (PubMed ID: 30513231)
1. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD).
Perugi G; Pallucchini A; Rizzato S; De Rossi P; Sani G; Maremmani AG; Pinzone V; Maremmani I
Expert Opin Pharmacother; 2019 Feb; 20(3):343-355. PubMed ID: 30513231
[TBL] [Abstract][Full Text] [Related]
2. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us?
Wilens TE; Monuteaux MC; Snyder LE; Moore H; Whitley J; Gignac M
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):787-98. PubMed ID: 16262595
[TBL] [Abstract][Full Text] [Related]
3. Attention-deficit/hyperactivity disorder and early-onset substance use disorders.
Wilson JJ; Levin FR
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):751-63. PubMed ID: 16262592
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?
Carpentier PJ; Levin FR
Harv Rev Psychiatry; 2017; 25(2):50-64. PubMed ID: 28272130
[TBL] [Abstract][Full Text] [Related]
5. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
6. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
7. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
Skoglund C; Brandt L; D'Onofrio B; Larsson H; Franck J
Eur Neuropsychopharmacol; 2017 Nov; 27(11):1144-1152. PubMed ID: 28935267
[TBL] [Abstract][Full Text] [Related]
9. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
Klassen LJ; Bilkey TS; Katzman MA; Chokka P
Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450
[TBL] [Abstract][Full Text] [Related]
10. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
11. Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder.
Regnart J; Truter I; Meyer A
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):275-282. PubMed ID: 28686107
[TBL] [Abstract][Full Text] [Related]
12. The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study.
Brynte C; Aeschlimann M; Barta C; Begeman AHA; Bäcker A; Crunelle CL; Daigre C; De Fuentes-Merillas L; Demetrovics Z; Dom G; López LG; Icick R; Johnson B; Joostens P; Kapitány-Fövény M; Karsinti E; Kiefer F; Konstenius M; Levin FR; Luderer M; Markus W; Matthys F; Moggi F; Palma-Alvarez RF; Paraskevopoulou M; Ramos-Quiroga JA; Schellekens A; Soravia LM; Therribout N; Thomas A; van de Glind G; van Kernebeek MW; Vollstädt-Klein S; Vorspan F; van den Brink W; Franck J
BMC Psychiatry; 2022 Sep; 22(1):625. PubMed ID: 36151539
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.
Cunill R; Castells X; Tobias A; Capellà D
J Psychopharmacol; 2015 Jan; 29(1):15-23. PubMed ID: 25142405
[TBL] [Abstract][Full Text] [Related]
16. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.
Zulauf CA; Sprich SE; Safren SA; Wilens TE
Curr Psychiatry Rep; 2014 Mar; 16(3):436. PubMed ID: 24526271
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD).
Perugi G; Pallucchini A; Rizzato S; Pinzone V; De Rossi P
Expert Opin Pharmacother; 2019 Aug; 20(12):1457-1470. PubMed ID: 31112441
[No Abstract] [Full Text] [Related]
18. Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician.
Barbuti M; Maiello M; Spera V; Pallucchini A; Brancati GE; Maremmani AGI; Perugi G; Maremmani I
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176536
[TBL] [Abstract][Full Text] [Related]
19. [Recommendations for the screening, diagnosis and treatment of patients with comorbid attention deficit hyperactivity- and substance use disorder].
Kapitány-Fövény M; Barta C; Crunelle CL; van den Brink W; Moggi F; Konstenius M; Franck J; Levin FR; van de Glind G; Coetzee C; Luderer M; Schellekens A; Matthys F; Demetrovics Z;
Psychiatr Hung; 2020; 35(4):435-447. PubMed ID: 33263293
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characteristics of South African treatment-seeking patients with substance use disorder and co-occurring attention-deficit/hyperactivity disorder.
Coetzee C; Truter I; Meyer A
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1271-1280. PubMed ID: 33040639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
